Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

JQKD82 is a prodrug form of KDM5-C49, an inhibitor of Jumonji AT-rich interactive domain 1A (JARID1A), also known as lysine-specific demethylase 5A (KDM5A).1 It increases the levels of trimethylated lysine 4 on histone 3 (H3K4me3) in MOLP-8 and MM.1S multiple myeloma cells when used at concentrations of 0.3 and 1 µM. JQKD82 reduces the proliferation of MOLP-8 and MM.1S cells in a concentration-dependent manner and decreases the viability of primary CD138+ cells from patients with multiple myeloma when used at a concentration of 3 µM. It induces cell cycle arrest at the G0/G1 phase, as well as induces apoptosis, in MOLP-8 and MM.1S cells when used at a concentration of 1 µM. JQKD82 (50 mg/kg twice per day) decreases tumor growth and increases survival in a MOLP-8 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Lysine demethylase 5A is required for MYC-